—
C+
C+ The full Closelook — membership. Open the C+ overview

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-09-18 — scores re-bake nightly. Cohort = shared Closelook index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 11 of 13 in its cohort on the Closelook composite (48/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 48 27 55 61 warn 19.9%
LLY Eli Lilly and Company 64 69 91 28 watch 10.8%
ORNAV.HE Orion Oyj A 62 78 83 34 ok 1.6%
ORNBV.HE Orion Oyj B 62 78 83 34 ok 1.6%
SAN.PA Sanofi SA 58 43 69 64 watch 12.8%
NVO Novo Nordisk A/S 56 46 86 73 bull 30.2%
AMGN Amgen Inc 54 65 84 44 watch 15%
EL.PA EssilorLuxottica S. A. 44 6 46 61 bear 55.3%
ABVX.PA Abivax SA 34 38 1 55 info 34.5%
BION.SW BB Biotech AG 74 74 96 81 info 8.2%
DXCM DexCom Inc 66 86 80 35 bull 5%
ARGX.BR Argen-X 65 79 75 28 ok 5.8%
ARGX argenx NV ADR 64 79 74 27 ok 7.7%

Scores are relative readings across the Closelook coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-18

Quick answers

Who are Virbac SA's peers in the Closelook universe?

The cohort is drawn from shared Closelook index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Sanofi SA (SAN.PA), Novo Nordisk A/S (NVO), Amgen Inc (AMGN), EssilorLuxottica S. A. (EL.PA), Abivax SA (ABVX.PA) and others.

How does VIRP.PA score against its peers?

Virbac SA's composite reads 48/100, ranking 11 of 13 in its cohort as of 2026-09-18; the cohort's highest composite is BB Biotech AG at 74/100. Closelook scores are research diary readings, not ratings or advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.